The Venture Codex

Participated · Series A · May 2026

BranchLab has built a privacy-first, AI-native platform that replaces fragmented, offline commercialization workflows for pharmaceutical companies by putting audience identification, activation, and optimization into near real-time use. Its transformer-based architecture allows models to be trained within customer-controlled environments while deploying only non-sensitive demographic and media-side signals. BranchLab says leading pharmaceutical companies use the platform and that it has driven an average increase of nearly 70% in marketing efficacy across therapeutic areas. The company is based in Boulder, Colo., and has raised a total of $35 million after closing a $26 million Series A. BranchLab plans to use the new funding to expand enterprise deployments, deepen integrations across the healthcare and media ecosystem, and further develop its unified AI commercialization platform.

Participated · Series A · Feb 2026

Founded in 2023 by Jen Wirt, Coral Care delivers pediatric speech, occupational, and physical therapy directly in children’s homes while equipping clinicians with software that handles credentialing, scheduling, billing, and documentation. The company operates in Massachusetts, New Hampshire, Texas, Illinois, and Pennsylvania, and has recently launched services in Dallas, Houston, Chicago, Philadelphia, and Pittsburgh. Coral Care’s network has grown to more than 400 licensed clinicians, and its platform reportedly cuts administrative workload by up to 15 hours per provider each week. More than 75% of families continue therapy for longer than four months, indicating strong engagement and retention. By embedding care in a child’s natural environment, the company aims to improve access, continuity, and contextual relevance of therapy. Coral Care plans to continue scaling its clinician base, enter additional markets, and further invest in its technology infrastructure using the newly raised capital. Its dual-sided model simultaneously increases provider supply and improves convenience for families seeking insurance-covered developmental care.

Participated · Series C · Nov 2025

Based in Brentwood, Tennessee, Spiras Health delivers personalized home-based care to people with complex chronic illnesses through a combination of in-person visits, telehealth, care coordination, and support for social determinants of health. Its nurse practitioner–led teams aim to improve health outcomes, reduce avoidable hospitalizations, and enhance quality of life for vulnerable, often underserved, populations. Operating under value-based care contracts, the company partners with health plans and focuses heavily on Duals Special Needs, Medicaid, and Medicare Advantage populations. With the latest financing, Spiras plans to broaden its product offerings and extend its services to additional states, targeting new market entries in Q1 2026. The company recently strengthened its leadership by appointing P. Nelson Le, MD, MBA, as Chief Medical Officer and Braden Manifold as Chief Financial Officer. Although specific revenue or user figures were not disclosed, Spiras previously raised $14 million in a 2021 Series B and continues to draw support from prominent healthcare investors.

Led · Series A · Nov 2025

IgniteData develops Archer, a platform that automates the movement of clinical trial data from source systems such as electronic health records (EHRs) to electronic data capture (EDC) systems and data warehouses. The technology reduces site burden, improves data quality and accelerates trial timelines by combining intelligent data mapping with generative AI. Following its recent financing, the company plans to expand its global research site network and deepen its work with large language models to unlock previously inaccessible clinical data. IgniteData collaborates with premier research centers and top pharmaceutical sponsors, positioning itself as a critical bridge between healthcare providers and life-science companies. Capital from the Series A will fund further product advancement and global scaling efforts. Although revenue or user metrics were not disclosed, the oversubscription of the round signals strong market demand and investor confidence.

Participated · Series C · Aug 2025

Wellth combines daily motivation, behavioral economics, and financial incentives to drive measurable behavior change for patients, encouraging actions like medication taking, blood pressure and glucose checks, and preventive visits. Its app delivers social‑media–like daily engagement designed to reach historically hard‑to‑reach Medicare Advantage, Medicaid, and D‑SNP populations. To date members have completed over 50 million daily check‑ins, achieving an average 90% care‑plan adherence, a 51% reduction in inpatient admissions, and a 16% improvement in medication adherence (PDC); the platform has helped partners attain 4+ Star ratings on Medicare Part C and D measures and reduce avoidable costs. Wellth will use new funding to broaden access across high‑need populations, accelerate product innovation and partner growth, and introduce generative AI capabilities to personalize motivation and care journeys. The company emphasizes a decade plus of behavioral data and outcomes as the basis for scaling its Daily Care Motivation approach. Wellth is based in Los Angeles and has been operating for 11 years. Wellth is a digital health company that applies behavioral economics and machine learning to drive daily health behaviors via a mobile app. Users perform simple daily tasks—such as snapping photos of medications or glucose readings—to form habits and increase adherence. The platform reports 91% daily member engagement and outcomes including a 42% average reduction in inpatient utilization, a 29% reduction in ED utilization, and a 16% improvement in medication adherence. Wellth's customers include health plans and provider organizations, and clients have measured cost savings and improved Medicare Advantage Star ratings. Founded in 2014 and headquartered in Los Angeles, the company has achieved impressive annual growth. The new capital will be used to further invest in the behavioral science engine behind the app and to expand the team to support a growing member base. Wellth provides a platform that uses behavioral economics, financial incentives and nudges to improve patient treatment adherence. Members submit scheduled virtual check-ins—typically daily—such as photos of medication or readings from glucometers and blood pressure cuffs. Check-ins are processed immediately by Wellth’s AI technology for verification, and insights can be relayed directly to care teams. Members keep an endowed daily amount and “cash out” at milestone intervals, creating instant gratification and reinforcing healthy habits. Led by CEO and co-founder Matthew Loper, the company plans to use new capital to expand its platform to new use cases. Wellth is based in New York City and recently raised a new funding round to support growth. Wellth is a Brooklyn-based behavioral economics startup that works with insurers and risk-bearing providers to motivate patient behavior change and treatment adherence. Its core product is a mobile patient experience that delivers daily contextual and personalized nudges and quick 'check-ins' for daily medications, using financial incentives and behavioral economics strategies. The company focuses on costly chronic diseases where poor adherence drives preventable hospitalizations and readmissions, including Type 2 Diabetes, Congestive Heart Failure, Cardiovascular Disease, COPD, Asthma and Behavioral Health. Wellth is led by CEO and co-founder Matt Loper. The company recently raised $5.1M in a Series A round to continue expanding its team and platform. It aims to help payers and providers better understand and improve patient behaviors to reduce costs associated with chronic disease management. Wellth is a digital health startup whose app tracks medication adherence, records weight, and uses incentives to motivate healthier lifestyle changes. CEO and co-founder Matt Loper said the company will use new funding to enable full-scale commercial implementations. Wellth has planned launches over the next six months and intends to generate data on interventions in type 2 diabetes, congestive heart failure, and post–heart attack discharge. The company’s near-term goal is to execute those implementations and publish data on impacts to adherence, health outcomes, and healthcare costs. Customers are insurers and risk-bearing providers, particularly in commercial and managed Medicaid markets, and Wellth typically charges on a per-user basis. The company says its actuarial model projects 4x+ returns after accounting for incentive payouts and Wellth fees.